EUCTR2020-005562-34-FR进行中（未招募）1 期
Integrative analysis of the tumor microenvironment and optimization of the immunotherapy duration in non-small cell lung cancer patients. OPTIMUNE-LUNG study - OPTIMUNE-LUNG
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Histologically or cytologically confirmed non-small cell lung carcinoma (squamous or non squamous).
- •2. Locally advanced/unresectable or metastatic disease.
- •3. Treatment with ICI (immune checkpoint inhibitor PD1/PDL-1 blockade therapy):
- •a. in first or second-line treatment as per market authorization. For patients in first line, ICI alone or ICI + chemotherapy,
- •b. start of ICI treatment 6 to 12 months (+/- 2 weeks) before registration.
- •4. At least one measurable lesion according to the RECIST v1.1 criteria before ICI treatment onset and confirmed by centralized review (lesion in previously irradiated filed can be considered as measurable if progressive at inclusion according to RECIST v1.1). At least one site of disease must be uni-dimensionally = 10 mm.
- •5. Patient with objective response (CR, PR) according to RECIST v1.1 criteria at 6 months or more and less than 12 months after ICI treatment onset. Response must be confirmed by centralized review on the basis of all CT scan carried out since the initiation of ICI treatment up to registration. PET-CT are also acceptable (several PET-CTs or CT scans compared with PET-CTs), under the following conditions:
- •a. Target lesions must be evaluable on PET-CT according to RECIST v1.1. This will be determined by the centralized radiologist at the time of the review. If target lesions are not evaluable according to RECIST v1.1, patient will not be eligible.
- •b. PET-CT is acceptable only for the centralized review. If not available, an additional CT scan must be performed within four weeks prior to registration (+1 week tolerance) to be used as baseline tumor assessment. Patient must be then followed using the same technique throughout the duration of the protocol.
- •6. At least one lesion that can be biopsied for research purpose. Note that in case of complete response or too small size lesion, the investigator must ensure the availability of suitable paraffin embedded (FFPE) archived tumor material (primary or metastatic site).
- •7. Age = 18.
- •8. Performance status = 2.
- •9. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to registration.
- •10. Patient with a social security in compliance with the French law (Loi Jardé).
- •11. Patient must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
- •12. Voluntarily signed and dated written informed consent prior to any study specific procedure.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 53
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 27
排除标准
- •1. Female who is pregnant or breast-feeding.
- •2. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study.
- •3. Hypersensitivity to one of the active substances or to one of the excipients
- •4. Any contraindication to pursue ICI treatment as per investigator judgement.
- •5. Previous enrolment in the present study.
- •6. Individual deprived of liberty or placed under legal guardianship.
研究者
相似试验
招募中
不适用
InteGRAtive Analysis of TuMor, Microenvironment, ImmunitY and Patient Expectation for Personalized Response Prediction in Gastric CancerGastric CancerNCT04842916Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori250
已完成
不适用
Comprehensive analysis of tumor immune microenvironment in small cell lung cancerSmall cell lung cancer (SCLC)JPRN-UMIN000041056Kindai university, Faculty of Medicine, Department of Medical Oncology340
招募中
不适用
Analysis of tumor immune microenvironments and host immune responses in cancer patientsmalignancyJPRN-UMIN000016678Kawasaki Medical School1,000
尚未招募
不适用
Characterizing the Tumor Immune Microenvironment of Head and Neck Squamous Cell Carcinomahead and neck cancerhead and neck squamous cell carcinoma10027655NL-OMON56910Amsterdam UMC1,600
招募中
不适用
Exploratory biomarker study on tumor microenvironment using pre-treatment and refractory archival samples of hepatocellular carcinomaJPRN-UMIN000047701Chiba University Hospital60